Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-MCBS Scorecards

ESMO MCBS  1000x150

The searchable portal provides a centralised location of cancer medicines that have been scored and published by ESMO.

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Tumour Stage Score Ref. Scorecard
Atezolizumab - Platinum-based chemotherapy First-line treatment of patients with high PD-L1 expression Thoracic Malignancies Non-small-cell Lung Cancer - Metastatic
Nivolumab - Single arm (Phase I/II) Metastatic with progression after platinum-based ChT and at least one other line of therapy regardless of PD-L1 status Thoracic Malignancies Small-cell Lung Cancer - Metastatic
Pembrolizumab - Single arm (Phase II) Metastatic with disease progression on or after platinum-based ChT and at least one other prior line of therapy Thoracic Malignancies Small-cell Lung Cancer - Metastatic
Encorafenib Binimetinib Vemurafenib Advanced unresectable or metastatic melanoma with a BRAF V600E or V600K mutation Skin Cancers Melanoma BRAF V600E or V600K Advanced unresectable or metastatic
Pembrolizumab ChT Placebo plus ChT 1st line treatment Breast Cancer Breast Cancer Triple-negative, PD-L1 (CPS >10) Locally recurrent inoperable or metastatic
Nivolumab - Single arm (Phase II) Treatment after failure of prior platinum-containing therapy Genitourinary Cancers Urothelial Carcinoma - Locally advanced unresectable or metastatic
Osimertinib 3 years - Placebo Adjuvant therapy after tumour resection Thoracic Malignancies Non-small-cell Lung Cancer EGFR exon 19 deletions or exon 21 (L858R) mutation Adjuvant
Margetuximab ChT Trastuzumab plus ChT Treatment of adult patients who have received two or more prior anti-HER2 regimes, at least one of which was for metastatic disease Breast Cancer Breast Cancer HER2+ Metastatic
Trastuzumab Deruxtecan - Either irinitecan or paclitaxel (Phase II) Previously treated on at least two prior regimes Gastrointestinal Cancers Gastric or gastro-oesophageal junction adenocarcinoma HER2+ Locally advanced or metastatic

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings